@article{26c2698924404b1e838254ce731c25ac,
title = "Immunotherapy combined with high- and low-dose radiation to all sites leads to complete clearance of disease in a patient with metastatic vaginal melanoma",
abstract = "A 73-year-old woman with metastatic vaginal mucosal melanoma that had progressed on ipilimumab and nivolumab experienced clinical and radiographic complete response to dual checkpoint inhibitor immunotherapy given in combination with high-dose plus low-dose radiation. General characteristics and treatment options in this disease are highlighted.",
keywords = "Abscopal effect, Immunotherapy, Low dose radiation, Vaginal mucosal melanoma",
author = "Duygu Sezen and Patel, {Roshal R.} and Christine Tang and Michaela Onstad and Priyadharsini Nagarajan and Patel, {Sapna P.} and Welsh, {James W.} and Lin, {Lilie L.}",
note = "Funding Information: The patient was treated on a trial supported by Varian Medical Systems and the National Cancer Institute (via Cancer Center Support Core Grant P30 CA016672 to The University of Texas MD Anderson Cancer Center ). Funding Information: The patient was treated on a trial supported by Varian Medical Systems and the National Cancer Institute (via Cancer Center Support Core Grant P30 CA016672 to The University of Texas MD Anderson Cancer Center).JWW reports research support from GlaxoSmithKline, Bristol Meyers Squibb, Merck, Nanobiotix, Reflexion, Alkermes, Artidis, Mavu Pharma, Takeda, Varian, and Checkmate Pharmaceuticals. JWW serves on the scientific advisory board for Legion Healthcare Partners, RefleXion Medical, MolecularMatch, Merck, AstraZeneca, Aileron Therapeutics, OncoResponse, CheckMate Pharmaceuticals, Mavu Pharma, Alpine Immune Sciences, Ventana Medical Systems, China Medical Tribune, GI Innovation and Nanorobotix. JWW is on Speakers Bureau for Ventana Medical Systems. He is co-founder of Healios, MolecularMatch, OncoResponse and serves as an advisor to Astra Zeneca, OncoResponse, Merck, MolecularMatch, Incyte, Aileron and Nanobiotix. JWW holds stock or ownership in Alpine Immune Sciences, Checkmate Pharmaceuticals, Healios, Mavu Pharma, Legion Healthcare Partners, MolecularMatch, Nanorobotix, OncoResponse, and RefleXion. JWW has accepted honoraria in the form of travel costs from Nanobiotix, RefleXion, Varian, Shandong University, The Korea Society of Radiology, Aileron Therapeutics and Ventana. JWW has the following patents; MP470 (amuvatinib), MRX34 regulation of PDL1, XRT technique to overcome immune resistance. MD Anderson Cancer Center has a trademark for RadScopal?. Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",
year = "2021",
month = jun,
doi = "10.1016/j.ygyno.2021.03.017",
language = "English (US)",
volume = "161",
pages = "645--652",
journal = "Gynecologic oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",
}